share_log

T2 Biosystems | 8-K: Entered into an Equity Distribution Agreement

T2 Biosystems | 8-K: Entered into an Equity Distribution Agreement

T2 Biosystems | 8-K:簽訂股權分銷協議
美股SEC公告 ·  07/19 15:21

Moomoo AI 已提取核心訊息

T2 Biosystems, a medical diagnostic company based in Lexington, Massachusetts, has officially terminated its Equity Distribution Agreement with Canaccord Genuity LLC as of July 19, 2024. The agreement, which was initially entered into on March 31, 2021, allowed for the sale of T2 Biosystems' common stock through an 'at the market' equity offering program where Canaccord served as the sales agent. The termination of the agreement carries no penalties for T2 Biosystems. Details of the original Equity Distribution Agreement can be found in the company's Registration Statement on Form S-3 filed with the SEC on the same date the agreement was signed.
T2 Biosystems, a medical diagnostic company based in Lexington, Massachusetts, has officially terminated its Equity Distribution Agreement with Canaccord Genuity LLC as of July 19, 2024. The agreement, which was initially entered into on March 31, 2021, allowed for the sale of T2 Biosystems' common stock through an 'at the market' equity offering program where Canaccord served as the sales agent. The termination of the agreement carries no penalties for T2 Biosystems. Details of the original Equity Distribution Agreement can be found in the company's Registration Statement on Form S-3 filed with the SEC on the same date the agreement was signed.
位於馬薩諸塞州萊剋星頓市的醫療診斷公司t2 biosystems已於2024年7月19日正式終止與Canaccord Genuity LLC的股權分銷協議。該協議最初於2021年3月31日簽訂,允許通過Canaccord作爲銷售代理商,進行t2 biosystems普通股股票的“市場定價”股權發行。該協議的終止對t2 biosystems不會產生任何處罰。有關原始股權分銷協議的詳細信息,可在公司於協議簽署當天提交的S-3表格註冊聲明中找到。
位於馬薩諸塞州萊剋星頓市的醫療診斷公司t2 biosystems已於2024年7月19日正式終止與Canaccord Genuity LLC的股權分銷協議。該協議最初於2021年3月31日簽訂,允許通過Canaccord作爲銷售代理商,進行t2 biosystems普通股股票的“市場定價”股權發行。該協議的終止對t2 biosystems不會產生任何處罰。有關原始股權分銷協議的詳細信息,可在公司於協議簽署當天提交的S-3表格註冊聲明中找到。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息